Attached files
file | filename |
---|---|
EX-32.1 - EX-32.1 - Oncotelic Therapeutics, Inc. | d312455dex321.htm |
EX-31.2 - EX-31.2 - Oncotelic Therapeutics, Inc. | d312455dex312.htm |
EX-31.1 - EX-31.1 - Oncotelic Therapeutics, Inc. | d312455dex311.htm |
EX-3.1 - EX-3.1 - Oncotelic Therapeutics, Inc. | d312455dex31.htm |
10-K - FORM 10-K - Oncotelic Therapeutics, Inc. | d312455d10k.htm |
Exhibit 23.1
Consent of Independent Registered Public Accounting Firm
We consent to the incorporation by reference in the following Registration Statements:
1. | Registration Statement (Form S-8 Nos. 333-126636, 333-177628, 333-181810 and 333-190409) pertaining to the Mateon Therapeutics, Inc. 2005 Stock Plan, as amended, |
2. | Registration Statement (Form S-8 No. 333-159585) pertaining to the Mateon Therapeutics, Inc. 2005 Stock Plan and the Mateon Therapeutics, Inc. 2009 Employee Stock Purchase Plan, and |
3. | Registration Statement (Form S-8 No. 333-204500) pertaining to the Mateon Therapeutics, Inc. 2015 Equity Incentive Plan |
of our report dated March 30, 2017 (which report expresses an unqualified opinion and includes an explanatory paragraph expressing substantial doubt about the Companys ability to continue as a going concern), with respect to the financial statements of Mateon Therapeutics, Inc., included in this Annual Report (Form 10-K) for the year ended December 31, 2016.
/s/ OUM & CO. LLP
San Francisco, California
March 30, 2017